In the primary human RCC cells (“RCC1”), SC66 treatment similarly reduced ROS production (Fig. 4k), mitochondrial depolarization (Fig. 4l), ceramide accumulation(Fig. 4m) and JNK activation (Fig. 4n). The gene discussed is RCC1; the disease is renal cell carcinoma.